Modality
Degrader
MOA
ALKi
Target
LAG-3
Pathway
Proteasome
HNSCC
Development Pipeline
Preclinical
~Mar 2022
→ ~Jun 2023
Phase 1
Sep 2023
→ Jun 2026
Phase 1Current
NCT06182754
862 pts·HNSCC
2023-09→2026-06·Terminated
862 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-06-213mo awayInterim· HNSCC
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P1
Termina…
Catalysts
Interim
2026-06-21 · 3mo away
HNSCC
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06182754 | Phase 1 | HNSCC | Terminated | 862 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| ALN-6288 | Alnylam | Approved | LAG-3 |